0QAV.L

Nanobiotix S.A. [0QAV.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

0QAV.L Stock Summary

Top 10 Correlated ETFs

0QAV.L

Top 10 Correlated Stocks

0QAV.L

In the News

0QAV.L Financial details

Company Rating
-
Market Cap
255.67M
Income
-101.72M
Revenue
9.4M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
101
Optionable
No
Shortable
Yes
Earnings
04 Sep 2024
P/E
-4.13
Forward P/E
-
PEG
-0.36
P/S
50.13
P/B
-4.51
P/C
-
P/FCF
-9.08
Quick Ratio
0.46
Current Ratio
0.67
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.92
EPS next Y
-
EPS next Q
-
EPS this Y
21.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.14%
Revenue last 5Y
6.54%
Revenue Q/Q
-4.47%
EPS Q/Q
-9.09%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-145%
ROE
145%
ROC
4.89%
Gross Margin
100%
Oper. Margin
-685%
Profit Margin
-872%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.624-10.38
52W High
-62.54%
52W Low
+274.6%
RSI
68
Rel Volume
0.15
Avg Volume
8.59K
Volume
1.25K
Perf Week
8.27%
Perf Month
24.87%
Perf Quarter
39.78%
Perf Half Y
12.16%
-
-
-
-
Beta
1.252
-
-
Volatility
0.15%, 0.25%
Prev Close
3.77%
Price
3.746
Change
6.72%

Something similar

Top by Market Cap
VTSAX
BRH.DE
BRYN.DE
V
AVGO
Top Correlated ETFs
307520.KS
VLED.PA
ZIN.TO
INR.DE
QUED.DE
Top Correlated Stocks
NANO.PA
MAI.L
ALIG.ST
002547.SZ
3LNV.L
Similar Market Cap
LCLEAN.ST
ORTINLAB.NS
8267.HK
MTLS
CDOFX

Company Profile

Healthcare Medical - Pharmaceuticals
  • Volume Average 8.59K
  • Market Capitalization 255.67M
  • Employee 101
  • CEO Mr. Laurent Levy Ph.D.
  • Headquarters Paris,FR
  • IPO Date 2014-02-13
  • Website https://www.nanobiotix.com

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.